News

Endo Pharmaceuticals has reported an increase in total revenue by 22% to $373.1 million for the second quarter of 2009, in comparison to $306.2 million in the second

BioMS Medical and Eli Lilly have reported that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS).

Quinnova has launched Salvax Duo, which contains one unit of Salvax Foam and one unit of Hydro 40 Foam. Salvax Duo is available by prescription only, and both

Anadys has received FDA clearance for its phase II protocol to study ANA598, in combination with pegylated interferonalpha and ribavirin, in hepatitis C patients. In the study, naive

Anadys has announced finalization of the protocol for its phase II trial of ANA598, in combination with pegylated interferon-alpha and ribavirin, in hepatitis C patients. Allowance of the

MeadWestvaco Corporation (MWV) reported positive second quarter earnings with year-over-year profit growth in the majority of the company’s business segments despite lower overall demand. Net sales for the

OmniComm Systems has reported that a US Clinical Research Organization (CRO) has selected OmniComm to provide eClinical solutions, in connection with two of the CRO’s phase IV studies.

MSM Protein Technologies (MSM) has entered into a drug discovery collaboration with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to create antibody-based products targeted to G-protein

Recordati has signed an exclusive license agreement with Pharmaplan for the marketing and sales of silodosin in South Africa. Silodosin is a new compound indicated for the treatment